Skip to content

Prognostic Study of Catheter Ablation Combined with Left Atrial Appendage Closure versus Left Atrial Appendage Closure Alone in Patients with Non-Valvular Atrial Fibrillation

Prognostic Study of Catheter Ablation Combined with Left Atrial Appendage Closure versus Left Atrial Appendage Closure Alone in Patients with Non-Valvular Atrial Fibrillation

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2500101744
Enrollment
Unknown
Registered
2025-04-29
Start date
2025-04-29
Completion date
Unknown
Last updated
2025-05-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Atrial fibrillation

Interventions

Catheter ablation combined with left atrial appendage occlusion group (CA LAAC group):None

Sponsors

Northern Jiangsu People's Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: Inclusion criteria in the left atrial appendage occlusion group: patients with non-valvular atrial fibrillation > age 18 years old and CHA2DS2-VASC score >=2 (female>=3) with one of the following conditions: 1 not suitable for long-term standardized anticoagulation therapy; 2. Thromboembolic events still occur on the basis of long-term standardized anticoagulation therapy; 3 HAS-BLED score >=3;4 requires concomitant antiplatelet therapy; 5. Unwilling to take long-term anticoagulation therapy Inclusion criteria for the catheter ablation combined with left atrial appendage closure group: 1. Meet the above inclusion criteria for left atrial appendage closure; 2. Symptomatic nonvalvular atrial fibrillation that is ineffective or intolerant of oral anti-arrhythmic drugs;

Exclusion criteria

Exclusion criteria: 1. Left atrial inner diameter>65mm; 2. TEE found thrombus in LAA; 3. Severe mitral valve disease or medium to large pericardial effusion; 4. Patients with acute ischemic stroke with intracranial hemorrhage caused by hemorrhagic transformation or oral anticoagulation therapy, and are not suitable for restarting anticoagulation therapy after multidisciplinary evaluation; 5. Coagulation dysfunction; 6. Patients with recent active bleeding; 7. Patients with other diseases that require continued anticoagulation in addition to AF; 8. Those who need to undergo surgical thoracotomy; 9. Acute myocardial infarction, NYHA cardiac function grade IV. 10. Transthoracic echocardiography (TTE) showed left ventricular ejection fraction (LVEF) < 30%;

Design outcomes

Primary

MeasureTime frame
Incidence of DRT;Incidence of residual fistula;Incidence of thromboembolic events;Cardiovascular mortality;

Secondary

MeasureTime frame
Heart failure readmission rate;All-cause mortality;

Countries

China

Contacts

Public ContactFangmei Liu

Northern Jiangsu People's Hospital

liufangmei4@126.com+86 514 8737 3262

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026